|Products||TransIT-siQUEST Transfection Reagent from Mirus Bio Corporation|
|Company||Mirus Bio Corporation|
|Item||TransIT-siQUEST Transfection Reagent|
|Description|| Cellular uptake of long double stranded RNA (dsRNA) has been shown to induce RNA interference in a diverse group of organisms as well as insect cells in culture. RNA interference leads to the inhibition of protein expression by utilizing sequence-specific, dsRNA-mediated destruction of the target messenger RNA (mRNA). Attempts to induce RNA interference using long dsRNA in mammalian cell lines have been met with limited success, due in part to the induction of the interferon response, which results in a general inhibition of protein synthesis. Recently, it has been shown that when short RNA duplexes are introduced into mammalian cells in culture, sequence-specific inhibition of target mRNA can be realized without introducing an interferon response. These short dsRNA, referred to as small interfering RNAs (siRNA), act catalytically at sub-molar ratios to cleave greater than 95% of the target mRNA in the cell. The RNA interference effect can be long-lasting and may be detectable after many cell divisions. These properties make siRNA extremely effective at inhibiting target gene expression.|
Mirus Corporation, in recognition of these significant findings, has developed TransIT-siQUEST Transfection Reagent, which enables highly efficient siRNA transfection with significantly reduced levels of cell damage as compared to cationic-liposome based transfection reagents. Transfections are most effective when carried out in complete growth media, with no media change or serum addition required. TransIT-siQUEST Reagent efficiently delivers siRNA to a wide range of cell lines, promoting high levels of target gene expression knockdown. These unique features make the TransIT-siQUEST Transfection Reagent ideal for siRNA-mediated gene silencing studies. The TransIT-siQUEST Reagent is a complement to Mirus popular TransIT-TKO siRNA Transfection Reagent. Each unique formulation provides a distinct transfection profile for high efficiency, broad-spectrum siRNA delivery.
|Info|| Mirus Bio Corporation|
505 S. Rosa Rd.
Madison, WI 53719
Fax Number: (608) 441-2849
Web Site: http://www.mirusbio.com